Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Guillain-Barre Syndrome Market Growth From $0.67 Billion In 2026 To $0.83 Billion By 2030 At A CAGR Of 5.4%
The guillain-barre syndrome market size has seen robust expansion in recent years. It is forecast to rise from $0.64 billion in 2025 to $0.67 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.6%. This historical growth can be ascribed to several contributors, including better identification of autoimmune neurological conditions, the broadening of hospital-based neurology departments, enhanced access to immunotherapy treatments, a surge in post-infectious complication cases, and superior critical care infrastructure.
The market for Guillain-Barré syndrome is projected to experience substantial expansion over the upcoming years. This market is set to reach a value of $0.83 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.4%. The anticipated growth during this period can be ascribed to several factors, including heightened investments in neurology research, a surging demand for cutting-edge immunomodulatory treatments, the broadening of specialized rehabilitation services, the expanding application of digital tools for neurological assessment, and an intensified emphasis on early intervention approaches. Key trends foreseen for the forecast timeframe encompass the increasing utilization of intravenous immunoglobulin therapies, the growing acceptance of plasma exchange procedures, a heightened focus on prompt neurological diagnosis, the proliferation of specialized neurology care centers, and more robust monitoring of autoimmune neurological conditions.
Get A Free Sample Report With In-Depth Market Insights:
Guillain-Barre Syndrome Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The growing prevalence of immunological diseases is anticipated to fuel the expansion of the guillain-barre syndrome market moving forward. Immunological diseases are characterized by an immune system that is either excessively active, insufficiently active, or misdirected, leading to conditions such as autoimmune diseases, allergies, or immunodeficiencies. The rise in immunological diseases stems from factors including environmental changes, lifestyle choices, enhanced diagnostic capabilities, and genetic susceptibility. These diseases can contribute to guillain-barré syndrome by triggering an autoimmune response where the body’s immune system mistakenly attacks its own peripheral nerves, resulting in inflammation and nerve damage. For instance, in July 2024, data from a report issued by the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Switzerland-based governmental body, revealed that by the end of 2022, an estimated 39.5 million people worldwide were living with HIV, with 1.3 million new infections and 630,000 AIDS-related deaths reported during that year. This number subsequently increased to around 39.9 million globally by 2023. Thus, the escalating risk of immunological diseases is a primary driver for the guillain-barre syndrome market.
Guillain-Barre Syndrome Market Segments: Where Is Growth Concentrated?
The guillain-barre syndrome market covered in this report is segmented –
1) By Type: Acute Inflammatory Demyelinating Polyneuropathy (AIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN)
2) By Therapeutics: Intravenous Immunoglobulin (IVIG), Plasma Exchange, Other Therapeutics
3) By End User: Hospitals, Specialty Neurology Clinics, Rehabilitation Centers, Home Healthcare Settings
Subsegments:
1) By Acute Inflammatory Demyelinating Polyneuropathy (AIDP): Classical AIDP, AIDP with Autonomic Involvement
2) By Miller Fisher Syndrome (MFS): Classical MFS, MFS With Ataxia, MFS With Ophthalmoplegia
3) By Acute Motor Axonal Neuropathy (AMAN): Classical AMAN, AMAN with Respiratory Involvement
Guillain-Barre Syndrome Market Innovation Trends: What Developments Are Reshaping The Industry?
Key players in the guillain-barre syndrome market are concentrating on innovative drug development, particularly monoclonal antibodies, to improve treatment efficacy, address existing clinical gaps, and broaden their market reach. Monoclonal antibodies are proteins engineered in laboratories to specifically target certain antigens, thereby helping to regulate immune responses and enhance therapeutic results. For example, in October 2023, Annexon Inc., a US-based biopharmaceutical company, obtained orphan drug designation from the European Medicines Agency (EMA) for its medicine ANX005 for the management of guillain-barre syndrome (GBS). This specific monoclonal antibody targets C1q, and has demonstrated early improvements in muscle strength and a decreased need for ventilation when compared to IVIg, positioning it as an important therapeutic breakthrough.
Guillain-Barre Syndrome Market Key Participants And Competitive Landscape
Major companies operating in the guillain-barre syndrome market are Pfizer Inc., Roche AG, AstraZeneca PLC, GSK plc, Takeda Pharmaceutical Company Limited, Merck & Co. Inc., Baxter International Inc., Biogen Inc., Horizon Therapeutics, Octapharma AG, Kedrion S.p.A., CSL Behring, Hansa Biopharma AB, Annexon Inc., Immunovant Inc., UCB S.A., Alexion Pharmaceuticals, Argenx SE, Grifols S.A., LFB S.A
View The Full Guillain-Barre Syndrome Market Report:
Guillain-Barre Syndrome Market Regional Breakdown: Where Is Demand Concentrated?
North America was the largest region in the guillain-barre syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
